BEGIN:VCALENDAR VERSION:2.0 PRODID:-//app.ishl.eu//Schedule X-WR-CALNAME:ISHL12 CALSCALE:GREGORIAN BEGIN:VTIMEZONE TZID:Europe/Berlin TZURL:http://tzurl.org/zoneinfo-outlook/Europe/Berlin X-LIC-LOCATION:Europe/Berlin BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:19700329T020000 RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:19701025T030000 RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-219@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T084500 DTEND;TZID=Europe/Berlin:20221022T101500 SUMMARY:Seminar 1 - Living beyond Lymphoma LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Patient perspective, Organisation of HL survivorship care in the UK, ADAPT program, Organisation of HL survivorship care in the Netherlands and design of INSIGHT costeffectiveness study, Organisation of HL survivorship care in the U.S. X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Seminar 1 - Living beyond Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-220@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T084500 DTEND;TZID=Europe/Berlin:20221022T101500 SUMMARY:Workshop 1 - The HL Microenvironment LOCATION:Kleiner Saal (Gürzenich) DESCRIPTION:Talks: Lessons from the Periphery – Single Cell Analyses of the Circulating Immune Signature in Hodgkin Lymphoma, Spatial Proteomic Analyses of the Intact Tumor Microenvironment in Hodgkin Lymphoma – One Cell or Region at a Time, Microenvironmental Lessons from the NIVAHL Trial X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 1 - The HL Microenvironment ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-221@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T084500 DTEND;TZID=Europe/Berlin:20221022T101500 SUMMARY:Workshop 2 - PET beyond Deauville LOCATION:Weinkeller (Gürzenich) DESCRIPTION:Talks: MTV and Baseline PET biomarkers, Latest developments in software and PET technology, Imaging response in the context of immunotherapy X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 2 - PET beyond Deauville ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-222@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T084500 DTEND;TZID=Europe/Berlin:20221022T101500 SUMMARY:Workshop 3 - Innovation for Older Patients LOCATION:Marsilius Saal (Gürzenich) DESCRIPTION:Talks: Lymphoma Biology and Immunosenescence in Older Patients, Efficacy and Safety of Targeted Drugs in Older HL Patients, Current and Future Trial Landscape in Older Patients, Open Discussion Forum: Adressing Unmet Needs X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 3 - Innovation for Older Patients ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-247@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T084500 DTEND;TZID=Europe/Berlin:20221022T101500 SUMMARY:Joint Symposium - Joint EHA-ISHL Symposium LOCATION:Ratsstube (Gürzenich) DESCRIPTION:Talks: Introduction to GHSG, In memoriam of Ton Hagenbeek, Future perspectives for prognostication and MRD in cHL, EV miRNA in cHL X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Joint Symposium - Joint EHA-ISHL Symposium ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-223@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T103000 DTEND;TZID=Europe/Berlin:20221022T120000 SUMMARY:Seminar 2 - Radiotherapy: Identifying the Beneficiaries LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Indications and current policy for radiotherapy in early and advanced stage HL based on GHSG randomized studies, Who benefits from adding radiotherapy even if PET-negative based on the RAPID study data, The experience of incorporating RT into CAR-T cell salvage programs- Does it apply to HL patients? X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Seminar 2 - Radiotherapy: Identifying the Beneficiaries ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-224@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T103000 DTEND;TZID=Europe/Berlin:20221022T120000 SUMMARY:Workshop 4 - Bringing Liquid Biopsy to Patients LOCATION:Kleiner Saal (Gürzenich) DESCRIPTION:Talks: Liquid Biopsy in Lymphoma: The Swiss Experience, Liquid Biopsy in Lymphoma: The Cologne experience , Integrating Fragmentomics and MRD in Lymphoma, Challenges in bringing Liquid Biopsy to Lymphoma patients – Kick-off talk for round table, Challenges in bringing Liquid Biopsy to Lymphoma patients – Round table X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 4 - Bringing Liquid Biopsy to Patients ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-225@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T103000 DTEND;TZID=Europe/Berlin:20221022T120000 SUMMARY:Seminar 3 - Learning from Pediatric HL LOCATION:Marsilius Saal (Gürzenich) DESCRIPTION:Talks: Framing the discussion and key issues in adolescent and young adult Hodgkin Lymphoma, Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma, SEARCH for CAYAHL initiative, Importance of QoL and PROs in long-term follow-up of HL, Development and execution of S1826 trial: North American NCTN pediatric/adult collaboration, Lessons from European Network for Pediatric Hodgkin Lymphoma X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Seminar 3 - Learning from Pediatric HL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-226@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T103000 DTEND;TZID=Europe/Berlin:20221022T120000 SUMMARY:Workshop 5 - NLPHL LOCATION:Weinkeller (Gürzenich) DESCRIPTION:Talks: Where belongs NLPHL? Biology and pathology, Treatment of NLPHL: what evidence is available?, The GLOW database: a tool to answer open questions in NLPHL X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Workshop 5 - NLPHL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-228@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T121500 DTEND;TZID=Europe/Berlin:20221022T134500 SUMMARY:Satellite Symposium - Opening paths to the next chapters of lymphoma treatmen LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: In memoriam of Saul Rosenberg, Welcome and Introduction to the topic, Hodgkin’s lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma, The challenge of the older patient in lymphoma therapy, New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Opening paths to the next chapters of lymphoma treatmen ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-229@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T140000 DTEND;TZID=Europe/Berlin:20221022T153000 SUMMARY:Scientific Session 1 - Early Stages LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Standard treatment of early-stage HL, Individual risk assessment of RT in HL, WS Report: NLPHL, Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies, Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial., Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 1 - Early Stages ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-230@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T160000 DTEND;TZID=Europe/Berlin:20221022T173000 SUMMARY:Satellite Symposium - CAR T cell therapy in B Cell NHL: Status quo and future perspectives LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Status quo of CAR T cell therapy for r/r DLBCL, New perspective for the treatment of r/r CLL, CAR T – Lessons Learned X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - CAR T cell therapy in B Cell NHL: Status quo and future perspectives ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-231@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T180000 DTEND;TZID=Europe/Berlin:20221022T190000 SUMMARY:Main Program - Opening and Award Ceremony LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Welcoming Address, Award Ceremony, Introduction to the Keynote Lecturer, Keynote Lecture X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Opening and Award Ceremony ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-232@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T190000 DTEND;TZID=Europe/Berlin:20221022T203000 SUMMARY:Main Program - Poster Session LOCATION:Foyer (Ground Floor) (Gürzenich) DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Poster Session ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-249@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221022T190000 SUMMARY:Main Program - Welcome Reception LOCATION:Kleiner Saal (Gürzenich) DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Welcome Reception ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-233@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221023T073000 DTEND;TZID=Europe/Berlin:20221023T090000 SUMMARY:Scientific Session 2 - Interactive Case Discussion LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Case presentation: Greyzone Lymphoma, Case presentation: Anti-PD1 Failure, Case presentation: COVID19 immunity in lymphoma, Case presentation: Primary progressive HL X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 2 - Interactive Case Discussion ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-234@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221023T091500 DTEND;TZID=Europe/Berlin:20221023T101500 SUMMARY:Scientific Session 3 - Emerging Cellular Therapies – a Role in HL? LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Clinical experience with Cellular Therapy in cH, Design and manufacturing of CD30 CARs for cHL, Emerging indications for cellular therapy X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 3 - Emerging Cellular Therapies – a Role in HL? ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-235@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221023T103000 DTEND;TZID=Europe/Berlin:20221023T120000 SUMMARY:Scientific Session 4 - Living beyond Lymphoma LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Towards Lung Cancer Screening in Hodgkin Lymphoma Survivors, GHSG data on fertility, fatigue and social reintegration and the ongoing EMBrACe study, WS Report: Living beyond Lymphoma, Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors, Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway, Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study. X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 4 - Living beyond Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-236@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221023T123000 DTEND;TZID=Europe/Berlin:20221023T133000 SUMMARY:Satellite Symposium - Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Firstline therapy of classical Hodgkin Lymphoma – How can immunotherapy improve outcome?, The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma, Strategies to enhance checkpoint inhibition X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-237@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221023T140000 DTEND;TZID=Europe/Berlin:20221023T153000 SUMMARY:Scientific Session 5 - Older and Frail Patients LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Managing an Older Lymphoma Patient, Treatment Strategies in Older HL Patients, Workshop Report: Innovation for Older patients, AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients., The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma, Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 5 - Older and Frail Patients ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-238@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221023T160000 DTEND;TZID=Europe/Berlin:20221023T173000 SUMMARY:Satellite Symposium - Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Welcome and introduction, Navigating Complex Treatment Decisions in R/R HL, Challenging Case Study #1, Learning from Real-World Evidence to Inform Treatment Decisions in R / R HL, Challenging Case Study #2, Audience Q&A X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-239@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221023T180000 DTEND;TZID=Europe/Berlin:20221023T193000 SUMMARY:Scientific Session 6 - Immunotherapy LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: New findings and new challenges since last ISHL, Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume, Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma ,Vision Corner Stimulus Talk: The future of translational science in HL ,Vision Corner Stimulus Talk: Best use of PD1 blockade in frontline treatment ,Vision Corner Stimulus Talk: Leveraging PD1 blockade for cure ,Vision Corner: Discussion X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 6 - Immunotherapy ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-240@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221024T073000 DTEND;TZID=Europe/Berlin:20221024T090000 SUMMARY:Scientific Session 7 - Advanced Stages LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Why I recommend BV-AVD, Why I recommend PET-guided ABVD, Why I recommend PET-adapted escalated BEACOPP, Discussion forum: Challenging standard recommendations from a patient's, nurse's and physician's perspective, WS Report: Learning through International Collaboration, FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial, Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 7 - Advanced Stages ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-241@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221024T091500 DTEND;TZID=Europe/Berlin:20221024T101500 SUMMARY:Scientific Session 8 - Special Situations in HL LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: HL in Pregnancy, HIV-positive HL, alloSCT in the era of anti-PD1 X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 8 - Special Situations in HL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-242@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221024T103000 DTEND;TZID=Europe/Berlin:20221024T120000 SUMMARY:Scientific Session 9 - Genomics, Biology and Microenvironment LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Biological Classification of HL by Liquid Biopsy, Single Cell Transcriptomics of HL, WS Report: Bringing Liquid Biopsy to Patients, Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma, High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years, Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 9 - Genomics, Biology and Microenvironment ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-243@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221024T121500 DTEND;TZID=Europe/Berlin:20221024T134500 SUMMARY:Satellite Symposium - Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Welcome and introduction, Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1, Bridging the gap: Balancing efficacy and toxicity in three challenging case studies (A debate and audience discussion with our panel), Audience Q&A, Summary and close X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Satellite Symposium - Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-244@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221024T140000 DTEND;TZID=Europe/Berlin:20221024T153000 SUMMARY:Scientific Session 10 - Relapsed / Refractory HL LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: 1ˢᵗ Relapse of HL, Novel developments in R/R HL, WS Report: PET beyond Deauville, Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial., High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma, Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I) X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Scientific Session 10 - Relapsed / Refractory HL ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-245@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221024T153000 DTEND;TZID=Europe/Berlin:20221024T160000 SUMMARY:Main Program - Closing Remarks LOCATION:Großer Saal (Gürzenich) DESCRIPTION:Talks: Conference Highlights X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Closing Remarks ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT BEGIN:VEVENT DTSTAMP:20260611T094200 UID:session-246@app.ishl.eu/2022 DTSTART;TZID=Europe/Berlin:20221024T160000 DTEND;TZID=Europe/Berlin:20221024T163000 SUMMARY:Main Program - Farewell LOCATION:Foyer (First Floor) (Gürzenich) DESCRIPTION: X-ALT-DESC;FMTTYPE=text/html:View Online BEGIN:VALARM DESCRIPTION:Main Program - Farewell ACTION:DISPLAY TRIGGER:-PT15M END:VALARM END:VEVENT END:VCALENDAR